CoChat

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

Open access
Komori, Mika, Lin, Yen Chih, Cortese, Irene, Blake, Andrew, Ohayon, Joan, Cherup, Jamie, Maric, Dragan, Kosa, Peter, Wu, Tianxia, Bielekova, Bibiana · 2016 · Annals of Clinical and Translational Neurology
Cited by 151

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Objective: Inaccessibility of the inflammation compartmentalized to the central nervous system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in progressive multiple sclerosis (MS). The double blind combination of R ituximab by I ntra V enous and I ntra T hec A l injection versus placebo in patients with L ow‐I nflammatory SE condary progressive MS (RIVITALISE; NCT 01212094) trial was designed to answer: (1) Whether an induction dose of intravenous and intrathecal rituximab efficiently depletes CNS B cells? and (2) If so, whether this leads to global inhibition of CNS inflammation and slowing of CNS tissue destruction? Methods: Patients aged 18–65 years were randomly assigned to rituximab or placebo. Protocol‐stipulated interim analysis quantified the efficacy of B‐cell depletion. Results: The efficacy on cerebrospinal fluid (CSF) biomarkers failed to reach criteria for continuation of the trial. B‐cell‐related CSF biomarkers (sCD 21 and B‐cell activating factor) changed only in the active‐treatment arm. While CSF B cells were killed robustly (median −79.71%, P = 0.0176), B cells in CNS tissue were depleted inadequately (~−10–20%, P < 0.0001). Consequently, the T‐cell‐specific CSF biomarker sCD 27 decreased slightly (−10.97%, P = 0.0005), while axonal damage marker, neurofilament light chain did not change. Insufficient saturation of CD 20, lack of lytic complement, and paucity of cytotoxic CD 56 dim NK cells contribute to decreased efficacy of rituximab in the CNS. Interpretation: Biomarker studies reliably quantified complementary pharmacodynamic effects of rituximab in the CNS, exposed causes for poor efficacy and determined that RIVITALISE trial would be underpowered to measure efficacy on clinical outcomes. Identified mechanisms for poor efficacy are applicable to all CNS‐inflammation targeting monoclonal antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.293

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 151

Metadata

Authors
Komori, M., Lin, Y. C., Cortese, I., Blake, A., Ohayon, J., Cherup, J., Maric, D., Kosa, P., Wu, T., & Bielekova, B.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2016-02
Volume
3
Issue
3
Pages
166-179
ISSN
2328-9503 (ISSN-L)
OpenAlex
W2278613505
Cited by
151
References
7
FWCI
17.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. https://app.cochat.ai/papers/10.1002/acn3.293
The paper
Komori, M., Lin, Y. C., Cortese, I., Blake, A., Ohayon, J., Cherup, J., Maric, D., Kosa, P., Wu, T., & Bielekova, B. (2016). Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.293

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.